Svitlana Tyekucheva

Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.

Gadi D, Griffith A, Wang Z, Tyekucheva S, Rai V, Fernandes SM, Machado JH, Munugalavadla V, Lederer J, Brown JR.

Br J Haematol. 2022 Apr. 197(2):207-211. PMID: 35170759

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM.

Eur J Cancer. 2022 03. 164:39-51. PMID: 35172272

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.

Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR.

Blood. 2022 02 03. 139(5):686-689. PMID: 34788401

Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.

Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA.

Elife. 2021 12 23. 10. PMID: 34939926

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.

Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR.

Leukemia. 2022 03. 36(3):723-732. PMID: 34743191

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR.

Lancet Oncol. 2021 10. 22(10):1391-1402. PMID: 34534514

Transcriptional landscape of PTEN loss in primary prostate cancer.

Imada EL, Sanchez DF, Dinalankara W, Vidotto T, Ebot EM, Tyekucheva S, Franco GR, Mucci LA, Loda M, Schaeffer EM, Lotan T, Marchionni L.

BMC Cancer. 2021 Jul 26. 21(1):856. PMID: 34311724

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.

Murali I, Kasar S, Naeem A, Tyekucheva S, Khalsa JK, Thrash EM, Itchaki G, Livitz D, Leshchiner I, Dong S, Fernandes SM, Getz G, Johnson A, Brown JR.

Blood. 2021 07 08. 138(1):44-56. PMID: 33684943

Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.

Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Vander Heiden MG, Fiorentino M, Ebot EM, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2021 04. 30(4):751-756. PMID: 33500320

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.

Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA.

Am J Hematol. 2021 04 01. 96(4):E95-E98. PMID: 33373063